Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2013/064479external-prioritypatent/WO2014059238A2/en
Application filed by Isis Pharmaceuticals IncfiledCriticalIsis Pharmaceuticals Inc
Publication of MA37987A1publicationCriticalpatent/MA37987A1/en
Certains modes de réalisation concernent des composés et des compositions ciblés sur un récepteur d'androgène (ra) humain afin de réduire les teneurs en récepteur d'androgène dans une cellule, qui peuvent être utiles dans des procédés de traitement du cancer et d'inhibition de la croissance ou de la prolifération des cellules cancéreuses.Certain embodiments relate to compounds and compositions targeted to a human androgen receptor (?) To reduce androgen receptor levels in a cell, which may be useful in methods of treating cancer and inhibiting growth or proliferation of cancer cells.
MA37987A2012-10-112015-04-10
Modulation of androgen receptor expression
MA37987A1
(en)
Humanized antibody that binds to human cd19; isolated nucleic acid encoding said antibody; vector and host cell; composition and immunoconjugate; method to inhibit the growth of tumor cells expressing cd19.